Kim Andrea A, Rehle Thomas
1 Division of Global HIV and Tuberculosis, Center for Global Health, U.S. Centers for Disease Control and Prevention , Atlanta, Georgia .
2 School of Public Health and Family Medicine, University of Cape Town , Cape Town, South Africa .
AIDS Res Hum Retroviruses. 2018 Oct;34(10):863-866. doi: 10.1089/AID.2017.0316. Epub 2018 Jul 24.
A recent infection testing algorithm (RITA) that includes a test for recent HIV infection and a viral load (VL) test is the recommended strategy to estimate national HIV incidence, reducing false-recent misclassification to <1%. The inclusion of information on exposure to antiretroviral therapy (ART), as a supplement to VL testing, could improve RITA performance by further lowering false-recent misclassification of true long-term infection. In 2012, Kenya and South Africa conducted national population-based surveys that collected information on HIV recency (i.e., HIV antibody seroconversion, on average, in the past 130 days) using the Limiting Antigen avidity (LAg-Avidity) enzyme immunoassay, HIV RNA levels, and ART exposure among HIV-infected respondents aged 15-49 years. In Kenya, ART exposure was defined as testing positive for one or more antiretroviral (ARV) drugs using high-performance liquid chromatography coupled with tandem mass spectrometry, and, if not ARV-positive, self-reporting a history of ART exposure. In South Africa, ART exposure was defined as testing ARV-positive. Two RITA strategies were compared: RITA #1 defined recent infection as testing LAg-Avidity-recent with unsuppressed VL (HIV RNA ≥1,000 copies/ml), and RITA #2 defined recent infection as testing LAg-Avidity-recent with unsuppressed VL and, if unsuppressed, having no ART exposure. RITA-derived incidence among persons aged 15-49 years in Kenya was 0.9% on RITA #1 and 0.8% on RITA #2. In South Africa, RITA-derived incidence was 2.2% on RITA #1 and 1.7% on RITA #2. Among specimens testing recent with unsuppressed VL in Kenya and South Africa, 16.0% and 19.7% had evidence of ART exposure, respectively. Although the performance of a VL- and ART-based RITA was encouraging, additional research is needed across HIV-1 subtypes and subpopulations to calibrate and validate this algorithm.
一种近期感染检测算法(RITA),包括一项近期HIV感染检测和一项病毒载量(VL)检测,是估计全国HIV发病率的推荐策略,可将近期误诊率降低至<1%。纳入抗逆转录病毒疗法(ART)暴露信息,作为VL检测的补充,可通过进一步降低真正长期感染的近期误诊率来提高RITA的性能。2012年,肯尼亚和南非开展了全国性的基于人群的调查,收集了15至49岁HIV感染受访者的HIV近期感染情况(即平均在过去130天内的HIV抗体血清转化情况)、HIV RNA水平以及ART暴露信息。在肯尼亚,ART暴露被定义为使用高效液相色谱串联质谱法检测一种或多种抗逆转录病毒(ARV)药物呈阳性,若未检测到ARV阳性,则自我报告有ART暴露史。在南非,ART暴露被定义为检测ARV呈阳性。比较了两种RITA策略:RITA #1将近期感染定义为LAg-Avidity检测为近期且VL未被抑制(HIV RNA≥1000拷贝/ml),RITA #2将近期感染定义为LAg-Avidity检测为近期且VL未被抑制,并且在VL未被抑制的情况下无ART暴露。肯尼亚15至49岁人群中,RITA #1得出的发病率为0.9%,RITA #2为0.8%。在南非,RITA #1得出的发病率为2.2%,RITA #2为1.7%。在肯尼亚和南非,VL未被抑制且检测为近期感染的样本中,分别有16.0%和19.7%有ART暴露的证据。尽管基于VL和ART的RITA的性能令人鼓舞,但仍需要在HIV-1亚型和亚人群中开展更多研究,以校准和验证该算法。